Navigation Links
DelMar Pharmaceuticals to Present at the 25th Annual ROTH Capital Partners Growth Stock Conference
Date:3/11/2013

VANCOUVER, British Columbia and MENLO PARK, Calif., March 11, 2013 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar"), a clinical and commercial stage drug development company with a focus on the treatment of cancer, today announced that Jeffrey Bacha , President & CEO of DelMar, will present at the ROTH 25th Annual Growth Stock Conference in Laguna Niguel, CA at 5:00pm PDT on Monday, March 18th, 2013.

"We are pleased to present the DelMar story at the ROTH Conference," said Jeffrey Bacha .  "This conference will complement our proactive program of investor communications and increase our awareness to the financial community as a new public company."

Mr. Bacha's presentation will be available on line at http://wsw.com/webcast/roth27/dmpi.t/

About DelMar Pharma
DelMar Pharmaceuticals was founded in 2010 to develop and commercialize proven cancer therapies in new orphan drug indications where patients are failing modern targeted or biologic treatments. The Company's lead asset, VAL-083, is currently undergoing clinical trials in the United States as a potential treatment for refractory glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer.  VAL-083 benefits from extensive clinical research sponsored by the US National Cancer Institute, and is currently approved for the treatment of chronic myelogenous leukemia (CML) and lung cancer in China. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types via a novel mechanism of action.

Safe Harbor Statement
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including, our current reports on Form 8-K. We do not undertake to update these forward-looking statements made by us.

For further information, please visit www.delmarpharma.com; or contact Jeffrey A. Bacha , President & CEO  (604) 629-5989 or Booke & Company Investor Relations, admin@bookeandco.com.


'/>"/>
SOURCE DelMar Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. DelMar Pharmaceuticals Announces Completion Of $10.5 Million Oversubscribed Offering And Appointment Of Investor Relations Consultant
2. DelMar Pharmaceuticals Announces Appointment of John K. Bell to Board of Directors
3. DelMar Pharmaceuticals Announces $1.6 Million Closing in Private Placement
4. DelMar Pharmaceuticals Announces $1.0 Million Third Closing in Private Placement
5. DelMar Pharmaceuticals to Present Interim Clinical Data on VAL-083 in Refractory Glioblastoma at Society for Neuro-Oncology (SNO) Annual Meeting
6. OncoGenex Pharmaceuticals, Inc. Provides Update on Clinical Development Program and Reports Financial Results for Fourth Quarter and Year End 2012
7. Pipeline Initiatives, Partnerships to Drive Growth - Research Report on Pfizer, Theravance, ISIS Pharmaceuticals, Infinity Pharmaceuticals and Ironwood
8. AcelRx Pharmaceuticals to Hold Fourth Quarter 2012 Financial Results Conference Call and Webcast on March 12, 2013
9. Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2012 Financial Results
10. Inovio Pharmaceuticals Prices $15.1 Million Offering of Common Stock and Warrants
11. Receptos Determines Novel GPCR Structure, Achieves Key Milestone in Collaboration with Ono Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2020)... ... February 10, 2020 , ... Soter ... and bullying detection and alert system in the world for schools, has announced ... MO-based developer of emergency communications technology for schools, cities, and law enforcement. The ...
(Date:2/10/2020)... ... February 10, 2020 , ... A device that teaches toddlers to go ... a patented sleep training system for children, launching today on Kickstarter. Hush Buddy creates ... Hush Buddy Sleep System, getting a child to sleep soundly is as easy as ...
(Date:2/10/2020)... (PRWEB) , ... February 10, 2020 , ... The Relapsing Polychondritis Foundation is ... British GT driver, will be a Race for RP driver in 2020. ... against relapsing polychondritis (RP) and other autoimmune diseases. , Flewitt has spent the past ...
Breaking Medicine Technology:
(Date:2/13/2020)... ... ... A January 24 article from Refinery29 looks at trends in ... reports on a well-documented dramatic and ongoing increase over the last 20 years in ... knowledgeable and are asking about a number of both traditional plastic surgeries and very ...
(Date:2/11/2020)... LAWRENCEVILLE, N.J. (PRWEB) , ... February 11, 2020 ... ... and medical affairs services and solutions, today announced its move to a new, ... its growing global customer base alongside significant expansion in the development of digital ...
(Date:2/11/2020)... (PRWEB) , ... February 11, 2020 , ... ... dental laboratories across North America, is pleased to announce a $5,000 grant to ... Dental Services Group® (DSG) has generously donated to the Smiles for Everyone ...
(Date:2/10/2020)... ... ... A January 26 article on Live Science reports on why ... – not unlike the skin’s response to dangerous conditions like extreme heat or cold, ... potential damage being done and warn the individual to escape the situation. Pasadena-based dental ...
(Date:2/10/2020)... , ... February 10, 2020 , ... ... vice president in the company’s healthcare division. In this role, Nikki will support ... guide the company’s continued healthcare product development. , “The healthcare industry is ...
Breaking Medicine News(10 mins):